Local News

• Neurogen Corporation receives notification from Nasdaq  Neurogen announced that on August 26, 2008, it received notice from The Nasdaq Stock Market indicating that for the past 30 business days Neurogen's common stock has not met the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Global Market.
  Neurogen Corporation August 27, 2008  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc. August 26, 2008  
• Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program  Bristol-Myers Squibb Company and Pfizer provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
  Pfizer Inc. August 26, 2008  
• VYVANSE(R) now available in U.S. pharmacies nationwide in six dosage strengths  Shire Limited has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
  Shire August 26, 2008  
• Stanford to limit drug maker financing  Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school.
  The New York Times August 25, 2008  Gardiner Harris
• Barr confirms patent challenge of FazaClo(R) orally disintegrating tablets  Barr Pharmaceuticals confirmed that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Azur Pharma International in connection with its FazaClo(R) (clozapine) orally disintegrating tablets, 25mg and 100mg.
  Barr Pharmaceuticals, Inc. August 25, 2008  
• Genzyme and Medicines for Malaria Venture announce new collaboration with Advinus  Genzyme and Medicines for Malaria Venture announced a new collaboration with India’s Advinus Therapeutics. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria.
  Genzyme Corporation August 25, 2008  
• Patients taking Cymbalta(R) experienced reduced chronic low back pain in new study  Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.
  Eli Lilly and Company August 25, 2008  
• Cymbalta receives European approval for the treatment of generalised anxiety disorder  Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder.
  Eli Lilly and Company August 22, 2008  
• FDA approves Nplate(TM) for long-term treatment of adult chronic ITP  Amgen announced that the United States Food and Drug Administration has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP).
  Amgen August 22, 2008  

   (next 10 articles)